Trial Profile
SPIRIT PRIME Clinical Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Registrational; Therapeutic Use
- Acronyms SPIRIT PRIME
- Sponsors Abbott Laboratories
- 24 Apr 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Nov 2011 Primary endpoint 'Target-lesion-failure-rate' has been met.
- 02 Nov 2011 Planned End Date changed to 30 Apr 2016.